Literature DB >> 18269792

Multianalyte quantification of five sesqui- and ethyl ether oxy-mustard metabolites in human urine by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.

Doris H Ash1, Sharon W Lemire, Sara C McGrath, Lisa G McWilliams, John R Barr.   

Abstract

Sesqui- and oxy-mustards pose a significant threat to military forces and civilians because they are potent vesicants. We have developed an isotope-dilution high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method utilizing negative ion multiple reaction monitoring for the analysis of sesqui-mustard metabolites bis(2-hydroxyethylthio)alkanes (n = 1-5) and oxy-mustard metabolite bis(2-hydroxyethylthioethyl)ether in human urine. Relative standard deviations were < 10% and the reportable limits of detection were 1 ng/mL in 0.5 mL of urine. We applied this method to 100 samples collected from individuals with no known exposure to sesqui- or oxy-mustards, and no urines showed detectable levels of any of the analytes, suggesting that these metabolites may be used for monitoring exposure to sesqui- and oxy-mustards.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269792     DOI: 10.1093/jat/32.1.44

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  2 in total

1.  Mass spectrometric analysis of adducts of sulfur mustard analogues to human plasma proteins: approach towards chemical provenancing in biomedical samples.

Authors:  Maria Hemme; Alex Fidder; Debora van der Riet-van Oeveren; Marcel J van der Schans; Daan Noort
Journal:  Anal Bioanal Chem       Date:  2021-04-26       Impact factor: 4.142

2.  Adduct of the blistering warfare agent sesquimustard with human serum albumin and its mass spectrometric identification for biomedical verification of exposure.

Authors:  Marc-Michael Blum; Annika Richter; Markus Siegert; Horst Thiermann; Harald John
Journal:  Anal Bioanal Chem       Date:  2020-09-09       Impact factor: 4.142

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.